<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955237</url>
  </required_header>
  <id_info>
    <org_study_id>82546</org_study_id>
    <nct_id>NCT03955237</nct_id>
  </id_info>
  <brief_title>Perioperative Fluid Management According to the Preoperative and Perioperative Glucose Level</brief_title>
  <official_title>Perioperative Fluid Management According to the Preoperative and Perioperative Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <brief_summary>
    <textblock>
      Background:Hyperglycemia and hypoglycemia both cause detrimental side effects for pediatric&#xD;
      patients. Prolonged fasting time, age dependent physiological diffences and individual&#xD;
      differences of patients make complicated the perioperative fluid therapy. Isotonic&#xD;
      electrolyte solutions without glucose or with lower glucose concentrations recommended for&#xD;
      intraoperative period in pediatric patients.&#xD;
&#xD;
      Objective: The aim of this prospective study is to evaluate the different glucose&#xD;
      concentrations(without dextrose, 1 % dextrose+LR, 2 % dextrose+LR) in perioperative infusion&#xD;
      solutions according to preoperative blood glucose level to maintain normoglycemia in&#xD;
      pediatric patients.&#xD;
&#xD;
      Method: The consecutive 250 eligible pediatric patients aged between 6 months- 12 years with&#xD;
      ASA risk score of I-II undergoing surgery lasting less than four hours were enrolled the&#xD;
      study in six months period. Patient demographics, procedure, preoperative fasting time,&#xD;
      preoperative and postoperative glucose levels were documented. Lactate ringer (LR) solution&#xD;
      with % 2 glucose was infused to the patients with preoperative blood glucose level lower than&#xD;
      60 mg/dL, LR solution with % 1 glucose was used for the patients with preoperative blood&#xD;
      glucose level between 60-90 mg/dL, LR solution without glucose was used for the patients with&#xD;
      preoperative blood glucose level higher than 90 mg/dL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lactate ringer (LR) solution with % 2 glucose was infused to the patients with preoperative&#xD;
      blood glucose level lower than 60 mg/dL, LR solution with % 1 glucose was used for the&#xD;
      patients with preoperative blood glucose level between 60-90 mg/dL, LR solution without&#xD;
      glucose was used for the patients with preoperative blood glucose level higher than 90 mg/dL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 different type of fluid</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucose level</measure>
    <time_frame>perioperative period</time_frame>
    <description>blood glucose level measurement with finger stick monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hyperglysemia or hypoglysemia ratio</measure>
    <time_frame>perioperative</time_frame>
    <description>blood glucose level measurement with finger stick monitoring</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Perioperative Complication</condition>
  <arm_group>
    <arm_group_label>non glucose infusion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug:1% Dextrose infusion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% Dextrose infusion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Drug: dextrose containing infusion</intervention_name>
    <description>Drug: infusing dextrose containing or non glucose fluid according to blood glucose level</description>
    <arm_group_label>2% Dextrose infusion group</arm_group_label>
    <arm_group_label>Drug:1% Dextrose infusion group</arm_group_label>
    <arm_group_label>non glucose infusion group</arm_group_label>
    <other_name>drug: non dextrose containing infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Ä°nclusion criteria;&#xD;
&#xD;
          -  6 months- 12 years old, ASA I-II children&#xD;
&#xD;
          -  Undergoing surgery lasting less than four hours were enrolled the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Parenteral nutrition or enteral nutrition&#xD;
&#xD;
          -  Patient with metabolic disorders,&#xD;
&#xD;
          -  ASA III-IV patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 20, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Ayse Cigdem Tutuncu</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

